Our Magazine
Brussels Morning Online Newspaper
Sunday, February 28, 2021
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
No Result
View All Result
Home Europe

France’s Sanofi to assist in production of Pfizer COVID-19 vaccine

Ivan Fischer by Ivan Fischer
27 January 2021
in Europe
France’s Sanofi to assist in production of Pfizer COVID-19 vaccine
Share on FacebookShare on Twitter

Brussels (Brussels Morning) The French pharmaceutical company Sanofi will help supply more than 100 million doses of the Pfizer/BioNTech COVID-19 vaccine this year, after hitting a roadblock that is likely to significantly delay plans to develop its own vaccine,  according to a report in Le Figaro on Tuesday.

Sanofi announced last month that the vaccine it is developing in partnership with the British pharma giant GlaxoSmithKline had shown a sub-par immune response in older trial participants, and that this development would probably delay the expected launch to late 2021.

Helping right now

Reuters notes that the company has since been under pressure to seek ways of helping with COVID-19 vaccines developed by other drug manufacturers, which are currently having difficulties meeting the huge global demand for their shots.

“Since our main vaccine is a few months late, we asked ourselves how we could be of assistance now,” Sanofi CEO Paul Hudson told Le Figaro. 

Filling and packing

Sanofi has pledged to fill and pack more than 100 million doses of the Pfizer vaccine at its BioCampus facility in Frankfurt, Germany, as an interim measure while it continues working on its own two vaccine candidates.

In addition to the delayed recombinant protein-based vaccine, which the company still hopes could be improved to provide sufficient immune response in elderly patients, Sanofi is also developing a mRNA-based vaccine, similar in technology to Pfizer’s, in cooperation with the US-based biotech company Translate Bio. Talking to the French daily, Sanofi’s CEO confirmed that the company remains committed to both its vaccine projects.

Tags: COVID-19 vaccineMain-SliderSanofi
Ivan Fischer

Ivan Fischer

Ivan is a Zagreb-based journalist with extensive experience in covering European and global politics, economy and emerging technology challenges. He is a foreign policy reporter for the leading Croatian daily Jutarnji list, as well as an alumnus of several journalism training programmes organised by Thomson Reuters Foundation and Robert Bosch Stiftung.

Latest post

Romania’s strained health system leaves non-Covid patients behind

Romania’s strained health system leaves non-Covid patients behind

2 days ago
European Research Group wants Northern Ireland Protocol scrapped

European Research Group wants Northern Ireland Protocol scrapped

2 days ago

Most Read

  • The EU will not learn to speak the language of power as long as Germany does not

    The EU will not learn to speak the language of power as long as Germany does not

    0 shares
    Share 0 Tweet 0
  • For US Cybersecurity China is a bigger concern than Russia

    0 shares
    Share 0 Tweet 0
  • Consumption of plant-based alternatives is disconcerting to meat and dairy industries

    0 shares
    Share 0 Tweet 0
  • Biden Administration opens the door to international green energy know-how

    0 shares
    Share 0 Tweet 0
  • Why women make great leaders — lessons from the pandemic

    0 shares
    Share 0 Tweet 0

Subscribe
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT